China Molecular Diagnostics In Pharmacogenomics Market Size & Outlook

The molecular diagnostics in pharmacogenomics market in China is expected to reach a projected revenue of US$ 66.3 million by 2033. A compound annual growth rate of 7.8% is expected of China molecular diagnostics in pharmacogenomics market from 2025 to 2033.
Revenue, 2024 (US$M)
$34.2
Forecast, 2033 (US$M)
$66.3
CAGR, 2025 - 2033
7.8%
Report Coverage
China

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

China molecular diagnostics in pharmacogenomics market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Related Markets

China molecular diagnostics in pharmacogenomics market highlights

  • The China molecular diagnostics in pharmacogenomics market generated a revenue of USD 34.2 million in 2024 and is expected to reach USD 66.3 million by 2033.
  • The China market is expected to grow at a CAGR of 7.8% from 2025 to 2033.
  • In terms of segment, kits and assays was the largest revenue generating product in 2024.
  • Services is the most lucrative product segment registering the fastest growth during the forecast period.


Molecular diagnostics in pharmacogenomics market data book summary

Market revenue in 2024USD 34.2 million
Market revenue in 2033USD 66.3 million
Growth rate7.8% (CAGR from 2025 to 2033)
Largest segmentKits and assays
Fastest growing segmentServices
Historical data2021 - 2023
Base year2024
Forecast period2025 - 2033
Quantitative unitsRevenue in USD million
Market segmentationKits and assays, Reagents, Services
Key market players worldwideRoche Diagnostics, Qiagen NV, Thermo Fisher Scientific Inc, Illumina Inc, Agilent Technologies Inc, Genomind, OneOme, Myriad Genetics Inc, Invitae Corp, Abbott Molecular


Other key industry trends

  • In terms of revenue, China accounted for 4.9% of the global molecular diagnostics in pharmacogenomics market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In Asia Pacific, China molecular diagnostics in pharmacogenomics market is projected to lead the regional market in terms of revenue in 2033.
  • Japan is the fastest growing regional market in Asia Pacific and is projected to reach USD 55.6 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Molecular Diagnostics in Pharmacogenomics Market Companies

Name Profile # Employees HQ Website
Abbott Molecular View profile 51-100 Des Plaines, Illinois, United States, North America https://www.abbottmolecular.com/
OneOme View profile 11-50 Minneapolis, Minnesota, United States, North America http://oneome.com/
Genomind View profile 101-250 Chalfont, Pennsylvania, United States, North America http://www.genomind.com
Roche Diagnostics View profile - - -
Invitae Corp View profile 1700 1400 16th Street, San Francisco, CA, United States, 94103 https://www.invitae.com
Myriad Genetics Inc View profile 2700 320 Wakara Way, Salt Lake City, UT, United States, 84108 https://www.myriad.com
Qiagen NV View profile 5900 Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL https://www.qiagen.com
Agilent Technologies Inc View profile 17700 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 https://www.agilent.com
Illumina Inc View profile 9300 5200 Illumina Way, San Diego, CA, United States, 92122 https://www.illumina.com
Thermo Fisher Scientific Inc View profile 122000 168 Third Avenue, Waltham, MA, United States, 02451 https://www.thermofisher.com

China molecular diagnostics in pharmacogenomics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to molecular diagnostics in pharmacogenomics market will help companies and investors design strategic landscapes.


Kits and assays was the largest segment with a revenue share of 50.88% in 2024. Horizon Databook has segmented the China molecular diagnostics in pharmacogenomics market based on kits and assays, reagents, services covering the revenue growth of each sub-segment from 2021 to 2033.


Reasons to subscribe to China molecular diagnostics in pharmacogenomics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of China molecular diagnostics in pharmacogenomics market databook

  • Our clientele includes a mix of molecular diagnostics in pharmacogenomics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the China molecular diagnostics in pharmacogenomics market , including forecasts for subscribers. This country databook contains high-level insights into China molecular diagnostics in pharmacogenomics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

China molecular diagnostics in pharmacogenomics market size, by product, 2021-2033 (US$M)

China Molecular Diagnostics in Pharmacogenomics Market Outlook Share, 2024 & 2033 (US$M)

China molecular diagnostics in pharmacogenomics market size, by product, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online